aTyr Pharma (LIFE) Lifted to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of aTyr Pharma (NASDAQ:LIFE) from a hold rating to a buy rating in a research note released on Wednesday. Zacks Investment Research currently has $3.25 price objective on the biotechnology company’s stock.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
LIFE has been the subject of several other research reports. JPMorgan Chase & Co. cut aTyr Pharma from a neutral rating to an underweight rating in a report on Wednesday, February 14th. ValuEngine cut aTyr Pharma from a sell rating to a strong sell rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $4.56.
Large investors have recently bought and sold shares of the company. Deutsche Bank AG bought a new stake in shares of aTyr Pharma in the 4th quarter valued at approximately $199,000. Dimensional Fund Advisors LP lifted its stake in shares of aTyr Pharma by 44.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 25,676 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of aTyr Pharma in the 3rd quarter valued at approximately $455,000. Artal Group S.A. bought a new stake in shares of aTyr Pharma in the 3rd quarter valued at approximately $1,263,000. Finally, Renaissance Technologies LLC lifted its stake in shares of aTyr Pharma by 143.2% in the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock valued at $978,000 after purchasing an additional 164,500 shares during the last quarter. 60.06% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “aTyr Pharma (LIFE) Lifted to “Buy” at Zacks Investment Research” was originally published by Daily Political and is owned by of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2018/03/04/atyr-pharma-life-lifted-to-buy-at-zacks-investment-research.html.
About aTyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.